HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
2.235
-0.005 (-0.22%)
Sep 14, 2026, 3:15 PM EDT - Market open
HCW Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6.72 | 0.05 | 2.57 | 2.84 | 6.72 | - | |
Revenue Growth | 707.02% | -97.89% | -9.68% | -57.73% | 63.96% | - |
Cost of Revenue | 0.27 | 0.04 | 1.61 | 2.28 | 4.14 | - |
Gross Profit | 6.45 | 0.01 | 0.96 | 0.56 | 2.59 | - |
Selling, General & Admin | 7.35 | 8.34 | 22.83 | 13.44 | 8.41 | 5.3 |
Research & Development | 5.09 | 5.33 | 6.29 | 7.59 | 9.25 | 8.07 |
Operating Expenses | 12.63 | 13.67 | 29.12 | 26.28 | 17.67 | 13.37 |
Operating Income | -6.18 | -13.66 | -28.16 | -25.72 | -15.08 | -13.37 |
Interest Expense | -0.55 | -0.85 | -0.65 | -0.28 | -0.13 | - |
Other Non Operating Income (Expenses) | -2 | -0.2 | 0.09 | 0.76 | 0.49 | -0.06 |
EBT Excluding Unusual Items | -8.73 | -14.7 | -28.72 | -25.24 | -14.71 | -13.43 |
Gain (Loss) on Sale of Investments | -2.02 | -0.27 | - | 0.25 | -0.19 | - |
Asset Writedown | -1.5 | -1.5 | - | - | - | - |
Other Unusual Items | 7 | 6.52 | -1.3 | - | - | 0.57 |
Pretax Income | -5.25 | -7.96 | -30.02 | -24.99 | -14.9 | -12.86 |
Net Income | -5.58 | -7.96 | -30.02 | -24.99 | -14.9 | -12.86 |
Preferred Dividends & Other Adjustments | 15.83 | 14.34 | - | - | - | - |
Net Income to Common | -21.41 | -22.3 | -30.02 | -24.99 | -14.9 | -12.86 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 |
Shares Change | 285.74% | 116.30% | 7.97% | 0.30% | 90.84% | 296.07% |
EPS (Basic) | -27.18 | -63.78 | -185.75 | -166.96 | -99.83 | -164.46 |
EPS (Diluted) | -27.18 | -63.78 | -185.75 | -166.96 | -99.83 | -164.46 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -12.14 | -13.39 | -14.49 | -28.72 | -20.66 | -11.02 |
Free Cash Flow Per Share | -15.41 | -38.30 | -89.64 | -191.82 | -138.43 | -140.94 |
Gross Margin | 95.91% | 20.00% | 37.38% | 19.72% | 38.48% | - |
Operating Margin | -92.02% | -25192.71% | -1096.95% | -904.96% | -224.32% | - |
Profit Margin | -318.55% | -41117.24% | -1169.70% | -879.52% | -221.67% | - |
Free Cash Flow Margin | -180.58% | -24693.20% | -564.48% | -1010.51% | -307.36% | - |
EBITDA | -5.58 | -12.62 | -26.97 | -24.58 | -14.49 | -12.82 |
EBITDA Margin | -83.09% | - | - | - | -215.55% | - |
D&A For EBITDA | 0.6 | 1.04 | 1.18 | 1.14 | 0.59 | 0.54 |
EBIT | -6.18 | -13.66 | -28.16 | -25.72 | -15.08 | -13.37 |
EBIT Margin | -92.02% | - | - | - | -224.32% | - |